

Kate Cwynarski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2363974/publications.pdf>

Version: 2024-02-01

27
papers

1,168
citations

840776

11
h-index

677142

22
g-index

28
all docs

28
docs citations

28
times ranked

1382
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e217-e227.	4.6	442
2	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	4.6	258
3	Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 348-363.	2.5	104
4	Rituximab in primary central nervous system lymphoma—A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	1.7	54
5	MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e110-e121.	4.6	54
6	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	7.2	47
7	Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system—an international study of feasibility and efficacy in routine clinical practice. <i>British Journal of Haematology</i> , 2020, 189, 879-887.	2.5	41
8	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. <i>Blood Advances</i> , 2020, 4, 3586-3593.	5.2	36
9	The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper. <i>British Journal of Haematology</i> , 2020, 190, 708-714.	2.5	36
10	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	5.2	24
11	Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant. <i>Transplantation</i> , 2020, 104, 2582-2590.	1.0	12
12	Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous) Tj ETQq0 0 0 rgBT /Overlock 10 196, 507-522.	2.5	12
13	Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2019, 54, 1625-1631.	2.4	11
14	Advances in treatment of elderly primary central nervous system lymphoma. <i>British Journal of Haematology</i> , 2022, 196, 473-487.	2.5	10
15	Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021, 138, 2636-2636.	1.4	8
16	Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma; caution required. <i>American Journal of Hematology</i> , 2021, 96, E338-E339.	4.1	5
17	Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial. <i>Blood</i> , 2021, 138, 2492-2492.	1.4	4
18	Prolonged SARS-CoV-2 shedding in a person living with advanced HIV and diffuse large B-cell lymphoma: a case report. <i>Infectious Diseases</i> , 2022, 54, 529-533.	2.8	3

#	ARTICLE	IF	CITATIONS
19	Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial. <i>Blood</i> , 2019, 134, 353-353.	1.4	2
20	Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious. <i>Blood</i> , 2019, 134, 1564-1564.	1.4	2
21	Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance. <i>Blood</i> , 2020, 136, 1-2.	1.4	2
22	Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients. <i>Blood</i> , 2021, 138, 452-452.	1.4	1
23	LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1730-1733.	1.3	0
24	â€CARMENâ€™: is less, more? Lessons from trials in human immunodeficiency virusâ€™Burkitt lymphoma (HIVâ€™BL). <i>British Journal of Haematology</i> , 2021, 192, 13-14.	2.5	0
25	Sequencing therapies in Hodgkin lymphoma. <i>Lancet Haematology</i> , the, 2021, 8, e537-e539.	4.6	0
26	A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial. <i>Blood</i> , 2019, 134, 2879-2879.	1.4	0
27	Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG). <i>Blood</i> , 2021, 138, 1417-1417.	1.4	0